The rationale and design of the AASK cohort study.


Journal Article

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African Americans with hypertensive kidney disease who receive recommended anti-hypertensive therapy. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of three medications used as initial anti-hypertensive therapy (ramipril, metoprolol, and amlodipine) and two levels of BP control. Of the 1094 trial participants, approximately 650 to 700 individuals who have not reached ESRD will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socioeconomic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression: treatment of hypertension and use of renoprotective, anti-hypertensive medication. The minimum duration of follow-up in the Cohort Study is 5 yr (total of 9 to 12 yr, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.

Full Text

Duke Authors

Cited Authors

  • Appel, LJ; Middleton, J; Miller, ER; Lipkowitz, M; Norris, K; Agodoa, LY; Bakris, G; Douglas, JG; Charleston, J; Gassman, J; Greene, T; Jamerson, K; Kusek, JW; Lewis, JA; Phillips, RA; Rostand, SG; Wright, JT

Published Date

  • July 2003

Published In

Volume / Issue

  • 14 / 7 Suppl 2

Start / End Page

  • S166 - S172

PubMed ID

  • 12819323

Pubmed Central ID

  • 12819323

International Standard Serial Number (ISSN)

  • 1046-6673

Digital Object Identifier (DOI)

  • 10.1097/01.asn.0000070081.15137.c0


  • eng

Conference Location

  • United States